Sorin points out positive data for SonR sensor measurement


Study data from the Sorin-sponsored CLEAR (Clinical Evaluation on Advanced Resynchronisation) trial has shown significant improvement in heart failure patients’ response to cardiac resynchronisation therapy with the company's SonR automatic CRT optimisation system.

SonR is designed to provide weekly automatic optimisation during patient’s daily activities as an alternative to in-clinic manual echocardiography-based device settings. The system consists of a dedicated sensor embedded in the tip of a pacing lead implanted with the CRT device. The technology allows direct measurement of real-time cardiac contractility and uses this haemodynamic signal to optimise the device’s parameters for each individual patient at rest and exercise.

The CLEAR study, a prospective, multicentre, single-blind, randomised study conducted in 51 centres in eight European countries, enrolled 238 patients with severe HF (New York Heart Association (NYHA) functional class III and IV and a left ventricular ejection fraction (LVEF) <35 per cent. Study results at one year showed that with SonR’s regular automatic optimisation of the device’s atrio-ventricular and inter-ventricular delays, 76 per cent of patients were classified as improved, compared with 62 per cent in the group of patients with standard CRT programming (p=0.0285).

The SonR sensor measures patient’s cardiac muscle vibrations related to the first heart sound and transmits the data to the CRT-D device which uses them to determine the best settings for the patient. The measurements correspond to LVdP/dtmax, the gold standard for assessing left ventricular contractility, a key indicator of cardiac performance.

This article is tagged to:
Sector: Medical Devices
Geography: Italy